[go: up one dir, main page]

BR9913766A - Composto, e, processos para tratar a hipertensão, a inflamação, as reações alérgicas, a desgranulação de mastócitos, os tumores e a hipoxia cardìaca e proteger contra a isquemia cerebral, para determinar a presença de células de tumor que possuam uma alta concentração de receptores de adenosina a3 em um paciente e em uma amostra de célula, e para determinar a preesença de células residuais de tumor a seguir de remoção cirúrgica de um tumor - Google Patents

Composto, e, processos para tratar a hipertensão, a inflamação, as reações alérgicas, a desgranulação de mastócitos, os tumores e a hipoxia cardìaca e proteger contra a isquemia cerebral, para determinar a presença de células de tumor que possuam uma alta concentração de receptores de adenosina a3 em um paciente e em uma amostra de célula, e para determinar a preesença de células residuais de tumor a seguir de remoção cirúrgica de um tumor

Info

Publication number
BR9913766A
BR9913766A BR9913766-6A BR9913766A BR9913766A BR 9913766 A BR9913766 A BR 9913766A BR 9913766 A BR9913766 A BR 9913766A BR 9913766 A BR9913766 A BR 9913766A
Authority
BR
Brazil
Prior art keywords
tumor cells
adenosine
tumor
tumors
inflammation
Prior art date
Application number
BR9913766-6A
Other languages
English (en)
Inventor
Pier Giovanni Baraldi
Pier Andrea Borea
Original Assignee
King Pharmaceuticals Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Res & Dev filed Critical King Pharmaceuticals Res & Dev
Publication of BR9913766A publication Critical patent/BR9913766A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"COMPOSTO, E, PROCESSOS PARA TRATAR A HIPERTENSãO A INFLAMAçãO, AS REAçõES ALéRGICAS, A DESGRANULAçãO DE MASTóCITOS, OS TUMORES E A HIPOXIA CARDìACA E PROTEGER CONTRA A ISQUEMIA CEREBRAL, PARA DETERMINAR A PRESENçA DE CéLULAS DE TUMOR QUE POSSUAM UMA ALTA CONCENTRAçãO DE RECEPTORES DE ADENOSINA A~ 3~ EM UM PACIENTE E EM UMA AMOSTRA DE CéLULA, E PARA DETERMINAR A PRESENçA DE CéLULAS RESIDUAIS DE TUMOR A SEGUIR DE REMOçãO CIRúRGICA DE UM TUMOR". Os compostos das fórmulas descritas aqui em que R, R^ 1^, R^ 2^, R^ 3^ e A têm os significados dados no relatório descritivo, são dotados com atividade seletiva de agonista do receptor de adenosina A~ 3~. Estes compostos podem ser usados em uma composição farmacêutica para tratar distúrbios causados por uma ativação excessiva do receptor A~ 3~ ou pode ser usado em um aplicação de diagnóstico para determinar a ligação relativa de outros compostos ao receptor A~ 3~. Os compostos pode ser rotulados, por exemplo com rótulos fluorescentes ou radiorótulos e os rótulos usados in vivo ou in vitro para determinar a presença de células de tumor que possuam uma concentração alta de receptores da adenosina A~ 3~.
BR9913766-6A 1998-09-16 1999-09-15 Composto, e, processos para tratar a hipertensão, a inflamação, as reações alérgicas, a desgranulação de mastócitos, os tumores e a hipoxia cardìaca e proteger contra a isquemia cerebral, para determinar a presença de células de tumor que possuam uma alta concentração de receptores de adenosina a3 em um paciente e em uma amostra de célula, e para determinar a preesença de células residuais de tumor a seguir de remoção cirúrgica de um tumor BR9913766A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/154,435 US6448253B1 (en) 1998-09-16 1998-09-16 Adenosine A3 receptor modulators
US09/379,300 US6407236B1 (en) 1998-09-16 1999-08-23 Adenosine A3 receptor modulators
PCT/US1999/021103 WO2000015231A1 (en) 1998-09-16 1999-09-15 Adenosine a3 receptor modulators

Publications (1)

Publication Number Publication Date
BR9913766A true BR9913766A (pt) 2001-06-05

Family

ID=22551355

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913766-6A BR9913766A (pt) 1998-09-16 1999-09-15 Composto, e, processos para tratar a hipertensão, a inflamação, as reações alérgicas, a desgranulação de mastócitos, os tumores e a hipoxia cardìaca e proteger contra a isquemia cerebral, para determinar a presença de células de tumor que possuam uma alta concentração de receptores de adenosina a3 em um paciente e em uma amostra de célula, e para determinar a preesença de células residuais de tumor a seguir de remoção cirúrgica de um tumor

Country Status (27)

Country Link
US (2) US6448253B1 (pt)
JP (1) JP2002524519A (pt)
KR (1) KR100448555B1 (pt)
CN (1) CN1154494C (pt)
AT (2) AT414240B (pt)
AU (1) AU749211B2 (pt)
BR (1) BR9913766A (pt)
CA (1) CA2332007C (pt)
CH (1) CH692132A5 (pt)
DE (1) DE19983530T1 (pt)
DK (1) DK200100432A (pt)
ES (1) ES2204262B1 (pt)
FI (1) FI116624B (pt)
GB (1) GB2353527B (pt)
HU (1) HUP0102589A3 (pt)
ID (1) ID28100A (pt)
IL (1) IL156851A (pt)
LU (1) LU90687B1 (pt)
NO (1) NO318078B1 (pt)
NZ (1) NZ509149A (pt)
RO (1) RO121030B1 (pt)
RU (1) RU2250904C2 (pt)
SE (1) SE522578C2 (pt)
TR (1) TR200003461T2 (pt)
WO (1) WO2000015231A1 (pt)
YU (1) YU83600A (pt)
ZA (1) ZA200101626B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
JPWO2002062801A1 (ja) * 2001-02-05 2004-06-10 株式会社大塚製薬工場 トリアゾロキナゾリン及びピラゾロトリアゾロピリミジン誘導体、医薬組成物、アデノシンａ３受容体親和剤、眼圧低下剤、緑内障の予防及び治療のための製剤、並びに眼圧低下方法
ATE453647T1 (de) * 2001-11-30 2010-01-15 Schering Corp Adenosin a2a rezeptor antagonisten
HUP0105407A3 (en) * 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HK1082662A1 (zh) * 2002-05-30 2006-06-16 King Pharmaceuticals Research And Development Inc. 具有三环吡唑并三唑并嘧啶环结构的制药活性化合物及其使用方法
US20060100168A1 (en) * 2002-09-30 2006-05-11 The Trustee Of Boston University Method of treating cancer using adenosine and its analogs
WO2004032864A2 (en) * 2002-10-07 2004-04-22 Radiorx, Inc. X-nitro compounds, pharmaceutical compositions thereof and uses therof
DE60315863T2 (de) * 2002-10-22 2008-05-15 Can-Fite Biopharma Ltd. A3ar als ein marker für einen erkrankungszustand
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
US8236874B2 (en) * 2003-06-11 2012-08-07 3M Innovative Properties Company Compositions and method for improving the processing of polymer composites
US7402625B2 (en) * 2003-06-11 2008-07-22 3M Innovative Properties Company Compositions and method for improving the processing of polymer composites
JP4782693B2 (ja) * 2003-10-28 2011-09-28 シェーリング コーポレイション 置換５−アミノ−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ［１，５−ｃ］ピリミジンを調製するためのプロセス
US20060009504A1 (en) * 2003-12-19 2006-01-12 Schering Corporation Pharmaceutical compositions
WO2005113828A1 (en) * 2004-05-14 2005-12-01 King Pharmaceuticals Research & Development, Inc. Methods of diagnosing and prognosticating solid tumors and melanoma
US20060204502A1 (en) * 2004-11-22 2006-09-14 Borea Pier A Enhancing treatment of cancer and HIF-1 mediated disorders with adenosine A3 receptor antagonists
JP2008520746A (ja) * 2004-11-22 2008-06-19 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド アデノシンａ３受容体アンタゴニストを用いる癌及びｈｉｆ−１が介在する疾患の促進的治療
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
EP2300496A4 (en) * 2008-07-16 2012-04-25 King Pharmaceuticals Res & Dev ATHEROSCLEROSIS TREATMENT METHODS
TWI404931B (zh) * 2009-02-20 2013-08-11 Nat Synchrotron Radiation Res Ct 癌化生物樣本之檢測方法及其使用之檢驗試劑
US9199102B2 (en) 2009-07-21 2015-12-01 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation
PL2506716T3 (pl) * 2009-12-01 2017-10-31 Abbvie Inc Nowe związki tricykliczne
US8471041B2 (en) * 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
US8664247B2 (en) 2011-08-26 2014-03-04 Radiorx, Inc. Acyclic organonitro compounds for use in treating cancer
EP2763667B1 (en) 2011-10-07 2022-10-26 EpicentRx, Inc. Organonitro thioether compounds and medical uses thereof
US20140308260A1 (en) 2011-10-07 2014-10-16 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
US9227979B2 (en) * 2012-01-25 2016-01-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fluorescent antagonists of the A3 adenosine receptor
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
WO2016202935A1 (en) * 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US20170129902A1 (en) 2015-10-16 2017-05-11 Abbvie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-alpha]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
EA201891606A1 (ru) 2016-01-11 2019-02-28 Эписентарикс, Инк. Композиции и способы для внутривенного введения 2-бром-1-(3,3-динитроазетидин-1-ил)этанона
JP7332469B2 (ja) 2016-10-14 2023-08-23 エピセントアールエックス，インコーポレイテッド スルホキシアルキル有機窒素および関連のある化合物ならびに医学における使用のための医薬組成物
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
CN110392572A (zh) 2017-03-09 2019-10-29 艾伯维公司 治疗克罗恩病和溃疡性结肠炎的方法
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
RS63557B1 (sr) 2017-03-30 2022-10-31 iTeos Belgium SA Derivati 2-okso-tiazola kao inhibitori a2a i jedinjenja za upotrebu u lečenju kancera
WO2019010447A1 (en) 2017-07-07 2019-01-10 Epicentrx, Inc. COMPOSITIONS FOR PARENTERAL ADMINISTRATION OF THERAPEUTIC AGENTS
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
CN108864114B (zh) 2018-06-04 2020-11-06 应世生物科技(南京)有限公司 选择性a2a受体拮抗剂
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
WO2020103939A1 (zh) * 2018-11-22 2020-05-28 上海科技大学 三唑并环类化合物、其制备方法、中间体和应用
CN111004245B (zh) * 2019-12-11 2022-01-07 徐州医科大学 吡唑-嘧啶并咪唑类化合物、制备方法及其应用
US12233053B2 (en) 2021-05-04 2025-02-25 Oradin Pharmaceutical Ltd. Adenosine A3 receptor antagonists for treating aging skin and wounds
CN116854644B (zh) * 2023-07-06 2025-10-21 浙江大学 5-氨基-1-烷基-1h-1,2,3-三氮唑-4-甲酰胺类化合物及其制备和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
ES2051772T3 (es) * 1986-09-30 1994-07-01 Ciba Geigy Ag 2-sustituido-e-fusionado-(1,2,4)-triazol(1,5-c)pirimidinas, composiciones farmaceuticas y sus usos.
HU208693B (en) * 1991-02-22 1993-12-28 Egyt Gyogyszervegyeszeti Gyar Process for producing 1,2,4-triazolo (1,5-a) pyrimidinis derivatives and their carbicycli-tetrahydro-thiofurane-tetrahydrothiopyrane-, or tetrahydropyridine- condensated derivatives or medical preparatives containing them
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
AU7237294A (en) * 1993-07-27 1995-02-28 Kyowa Hakko Kogyo Co. Ltd. Remedy for parkinson's disease
IT1275420B (it) 1995-06-02 1997-08-05 Schering Plough S P A Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
US6066642A (en) * 1996-01-29 2000-05-23 The United States Of America As Represented By The Department Of Health And Human Services Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
US6326390B1 (en) * 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth

Also Published As

Publication number Publication date
ES2204262A1 (es) 2004-04-16
GB2353527A (en) 2001-02-28
SE522578C2 (sv) 2004-02-17
US6407236B1 (en) 2002-06-18
AU749211B2 (en) 2002-06-20
YU83600A (sh) 2003-12-31
WO2000015231A1 (en) 2000-03-23
WO2000015231A8 (en) 2000-06-15
CA2332007A1 (en) 2000-03-23
IL156851A (en) 2006-08-20
HUP0102589A3 (en) 2002-01-28
SE0003984D0 (sv) 2000-11-01
KR20010089154A (ko) 2001-09-29
WO2000015231A9 (en) 2000-08-17
DK200100432A (da) 2001-03-14
NZ509149A (en) 2003-08-29
ATA904399A (de) 2006-01-15
NO20005508D0 (no) 2000-11-01
US6448253B1 (en) 2002-09-10
HUP0102589A2 (hu) 2001-11-28
NO20005508L (no) 2001-03-15
ES2204262B1 (es) 2005-03-01
RU2250904C2 (ru) 2005-04-27
CH692132A5 (de) 2002-02-28
AT414240B (de) 2006-10-15
RO121030B1 (ro) 2006-11-30
CN1303289A (zh) 2001-07-11
ZA200101626B (en) 2001-12-13
SE0003984L (sv) 2000-12-22
CN1154494C (zh) 2004-06-23
HK1035671A1 (en) 2001-12-07
KR100448555B1 (ko) 2004-09-13
DE19983530T1 (de) 2001-11-08
LU90687B1 (en) 2000-12-19
FI20002367L (fi) 2001-01-19
ID28100A (id) 2001-05-03
GB2353527B (en) 2004-02-25
AU6248299A (en) 2000-04-03
AT503591A2 (de) 2007-11-15
GB0027879D0 (en) 2000-12-27
CA2332007C (en) 2007-08-07
JP2002524519A (ja) 2002-08-06
FI116624B (fi) 2006-01-13
NO318078B1 (no) 2005-01-31
TR200003461T2 (tr) 2001-06-21

Similar Documents

Publication Publication Date Title
BR9913766A (pt) Composto, e, processos para tratar a hipertensão, a inflamação, as reações alérgicas, a desgranulação de mastócitos, os tumores e a hipoxia cardìaca e proteger contra a isquemia cerebral, para determinar a presença de células de tumor que possuam uma alta concentração de receptores de adenosina a3 em um paciente e em uma amostra de célula, e para determinar a preesença de células residuais de tumor a seguir de remoção cirúrgica de um tumor
BR0210720A (pt) Composto e uso do mesmo
Geh et al. Multiple pilomatrixomata and myotonic dystrophy: a familial association
Malinoff et al. Isolation of a cell surface receptor protein for laminin from murine fibrosarcoma cells.
RU2646481C2 (ru) Композиции и способы лечения сердечной недостаточности
BRPI0409678A (pt) métodos para identificar um composto, para tratar ou prevenir uma doença ou distúrbio em um humano, para incrementar a função de órgãos, tecidos, ou células excitáveis em um humano e para modular a atividade de um complexo de receptores de citocinas protetor de tecidos em um humano
BR0111220A (pt) Conjugados de fármacos de etilenocisteìna (ec)
O'Loughlin et al. Hidradenitis suppurativa: glucose tolerance, clinical, microbiologic, and immunologic features and HLA frequencies in 27 patients
CA2042569A1 (en) Stabilized fgf composition
Sieja et al. Concentration of histamine in serum and tissues of the primary ductal breast cancers in women
BR112022026550A2 (pt) Composição de compostos que modulam o metabolismo celular e métodos de uso
BR112022014245A2 (pt) Compostos de modulação do metabolismo celular inovadores e usos dos mesmos
Yorifuji et al. Decreased activities in mitochondrial inner membrane electron transport system in muscle from patients with Kearns-Sayre syndrome
Raynaud et al. Retinoid treatment of human psoriatic fibroblasts induces an increase in cyclic AMP-dependent protein kinase activity
Ohashi et al. Antagonistic effect of KC-404, a new anti-asthmatic agent, on leukotriene D4-induced contractile responses in isolated guinea pig smooth muscles
MA26726A1 (fr) Composition pharmaceutique de resorcinol, et procede pour sa preparation
Saito et al. Effect of retinoic acid and 12-O-tetradecanoyl phorbol-13-acetate on the binding of epidermal growth factor to its cellular receptors
Sugiura et al. Regional differences in myosin heavy chain isoforms and enzyme activities of the rat diaphragm
US11672797B2 (en) Methods of treating keloids
Chen et al. Tyrosol promotes skin flap survival by downregulating the p38/NF-κB signaling pathway
Sieja et al. Histamine and epidermal growth factor in women with fibrocystic changes of the breast
Davis et al. Modulation of type α transforming growth factor receptors by a phorbol ester tumor promoter
Sakuraoka et al. Biochemical analyses of macromolecular matrix components in patients with pseudoxanthoma elasticum
Scholz et al. Effects of caffeine, halothane, succinylcholine, phenylephrine and isoproterenol on myocardial force of contraction of malignant hyperthermia susceptible swine
SIPES et al. Some cardiovascular and autonomic effects of fenfluramine hydrochloride

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.